Evaluate the Neurological Effects of EryDex on Subjects With A-T
NCT06193200
Recruiting
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
04/02/2025
Locations: University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California +21 locations
Conditions: Ataxia Telangiectasia
Register for Updates
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
NCT06311578
Recruiting
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania +6 locations
Conditions: Advanced Solid Tumors
Register for Updates
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204
Recruiting
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +162 locations
Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Register for Updates
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
NCT06559176
Recruiting
This is an open-label, single-arm, multicenter Phase 1/2 study evaluating the safety and efficacy of gene therapy by transplantation of Prime Edited autologous CD34+ stem cells modified ex vivo (PM359) in participants with autosomal recessive Chronic Granulomatous Disease (CGD) caused by mutations in the NCF1 (Neutrophil Cytosolic Factor 1) gene.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
04/02/2025
Locations: University of California Los Angeles Medical Center, Los Angeles, California +4 locations
Conditions: Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Register for Updates
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908
Recruiting
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +8 locations
Conditions: Advanced Solid Tumor
Register for Updates
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06701656
Recruiting
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort C: Participants will be randomized to receive either a placebo or bevacizumab. This record describes the default procedures and analyses for Cohort C. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: St. Luke's Boise Medical Center, Boise, Idaho +1 locations
Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Register for Updates
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236
Recruiting
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: UCSF - Helen Diller Family Cancer Center, San Francisco, California +5 locations
Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
Register for Updates
BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRD
NCT06803797
Recruiting
This 12-week trial will test the efficacy of a multi-component, personalized text-message delivered behavior change technique (BCT) intervention to encourage habitual physical activity (defined as regular walking of 1,000 or more steps during a one-hour period on 7 consecutive days according to a personalized walking plan) among care providers of persons with AD/ADRD via the key mechanism of behavior change (MoBC) of automaticity. The main question it aims to answer whether a multi-component, p... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/02/2025
Locations: Institute of Health System Science, New Hyde Park, New York
Conditions: Inactivity, Physical
Register for Updates
MOTION Clinical Trial
NCT06843980
Recruiting
Prospective, multicenter, two-arm, 2:1 randomized controlled trial (RCT) comparing the benefits in subjects with medial knee osteoarthritis who are treated with either the MISHA Knee System or with non-surgical treatment. This is the first randomized head-to-head study comparing outcomes from subjects treated with the MISHA Knee System.
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2025
Locations: Scripps Clinic Jefferson, Oceanside, California +3 locations
Conditions: Osteoarthritis, Knee
Register for Updates
Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)
NCT06908057
Recruiting
The purpose of this study is to identify people with T1D or celiac disease (CD) early in the course of their disease and to improve the methods of screening for these diseases.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/02/2025
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Type 1 Diabetes, Celiac Disease
Register for Updates
Impact of Vitamin D Supplements on Mental Health and Milk Composition in Mothers Living in Idaho
NCT06919718
Recruiting
Mothers of preterm infants experience exaggerated emotional stressors compared to those typically associated with new motherhood, making these women particularly vulnerable to postpartum depression. As many as 70% of mothers of preterm infants experience postpartum depression compared to only 12.5% of those delivering full-term infants. Increased stress and depression during this critical period are detrimental because they hamper a mother's ability to care for her infant and are associated with... Read More
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
04/02/2025
Locations: Kootenai Health, Coeur d'Alene, Idaho +1 locations
Conditions: Maternal Stress
Register for Updates
Inflammation, Diabetes, Ethnicity and Obesity Cohort
NCT03022682
Recruiting
Obesity affects over one third of US adults (\>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the mo... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/02/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Obesity, Diabetes Mellitus, Pre Diabetes
Register for Updates